Niti Mohan, PA
Endocrinology, Diabetes & Metabolism · Smithtown, NYNPI 1912531542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,659 and has fallen 95.9% since, to $149 in 2025.
Across 403 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Lilly USA, LLC$822
- Mannkind Corporation$770
- Insulet Corporation$635
- Amgen$619
- Xeris Pharmaceuticals, Inc.$522
- plus $4K from 29 others
What the payments were for
- Food & beverage$8,565100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 37 | $1,014 |
| Lilly USA, LLC | 35 | $822 |
| Mannkind Corporation | 40 | $770 |
| Insulet Corporation | 31 | $635 |
| Amgen | 31 | $619 |
| Xeris Pharmaceuticals, Inc. | 27 | $522 |
| Intuity Medical Inc | 17 | $476 |
| Medtronic | 21 | $421 |
| Esperion Therapeutics, Inc. | 10 | $401 |
| Sanofi-aventis U.S. LLC | 16 | $323 |
| Novo Nordisk | 22 | $318 |
| Currax Pharmaceuticals LLC | 15 | $256 |
| Dexcom, Inc. | 15 | $235 |
| Bayer | 6 | $159 |
| Tandem Diabetes Care, Inc. | 8 | $151 |
| Abbott | 2 | $149 |
| Radius Health, Inc. | 9 | $141 |
| Ascensia Diabetes Care US Inc. | 6 | $132 |
| Corcept Therapeutics | 7 | $131 |
| Amneal Pharmaceuticals LLC | 7 | $123 |
| AstraZeneca | 6 | $120 |
| Kowa Pharmaceuticals America, Inc. | 8 | $117 |
| IBSA Pharma Inc. | 4 | $83 |
| Novartis | 5 | $73 |
| Zealand Pharma US, Inc. | 3 | $61 |
| Cequr Corporation | 1 | $58 |
| Merck | 4 | $57 |
| Amryt Pharma Holdings Ltd | 2 | $43 |
| AbbVie | 1 | $29 |
| Clarus Therapeutics Inc. | 2 | $28 |
| Nevro Corp. | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Johnson & Johnson | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,565 in reported general payments places this provider in the 80th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Smithtown
- Michael ShanikSmithtown$1.2M
- David KuglerSmithtown$95K
- Sherry SussmanSmithtown$70K
- Robert BuschAlbany$2.7M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.